Live Breaking News & Updates on ஜோஷ் ஸ்மைலி|Page 3

Stay updated with breaking news from ஜோஷ் ஸ்மைலி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chutes & Ladders—After Verastem pit stop, bluebird vet Neumann lands at Kite


Editas Medicine 
James Mullen takes over as CEO from Feb. 15.
Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief
Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from ....

New York , United States , British Columbia , United Kingdom , Bryan Lake , San Francisco , Bhardwaj Desai , Cynthia Collins , Penrose Therapeutx , Daniel Lynch , Shannon Blalock , Fraiser Kansteiner , Eli Lilly , Patrick Mccall , Josh Smiley , Joel Sendek , Tim Trost , Isaac Ro , Guowei Fang , Charlie Newton , Lyell Immunopharma , Manny Duenas , Geoffrey Mcdonough , James Priour , David Enloe , Terry Coelho ,

Eli Lilly CFO steps down—and gives up $24M-plus in cash and equity—after investigation finds 'inappropriate' behavior


Feb 9, 2021 8:11am
Eli Lilly tapped a new CFO after finding its former top finance exec engaged in consensual though inappropriate personal communications with employees.
After Eli Lilly heard allegations of an inappropriate relationship between its chief financial officer, Josh Smiley, and an employee, the drugmaker hired an external firm to investigate. Now, Smiley is not only out of the job, but also forfeiting $24 million in cash and equity awards.
Smiley, who s served as CFO since the start of 2018, is leaving the company, Lilly said Tuesday. Anat Ashkenazi, previously senior vice president, controller and chief financial officer of Lilly Research Laboratories, will take the post.  ....

Josh Smiley , David Ricks , Lilly Research Laboratories , Eli Lilly , After Eli Lilly , Anat Ashkenazi , Management Changes , ஜோஷ் ஸ்மைலி , டேவிட் ரிக்ஸ் , லில்லி ஆராய்ச்சி ஆய்வகங்கள் , எலி லில்லி , மேலாண்மை மாற்றங்கள் ,